Breast Cancer Update

HER2-Low and HER2-Ultralow Breast Cancer — A Roundtable Discussion on Current and Future Management Strategies Feb 15, 2025

Dr Joyce O’Shaughnessy from Sarah Cannon Research Institute in Dallas, Texas, Dr Mark D Pegram from Stanford Cancer Institute in California, and Prof Peter Schmid from Barts Cancer Institute in London, United Kingdom, summarize currently available data guiding treatment decision-making for patients with low and ultralow HER2 expression and present cases from their practices.

CME information and select publications here.

5-Minute Journal Club Issue 4 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer Feb 10, 2025

Dr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer.

CME information and select publications here

5-Minute Journal Club Issue 3 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer Jan 31, 2025

Dr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer.

CME information and select publications here

Metastatic Triple-Negative Breast Cancer — Oncology Q&A for Clinicians: Discussing Common Questions Posed by Patients Jan 24, 2025

Dr Lisa A Carey from UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, and Dr Rita Nanda from the University of Chicago in Illinois address commonly asked questions from patients diagnosed with metastatic triple-negative breast cancer.

CME information and select publications here

Oncology Q&A for Patients with Metastatic Triple-Negative Breast Cancer Jan 17, 2025

For this patient-focused webinar, medical oncologist Dr Neil Love is joined by Dr Lisa A Carey from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill and Dr Rita Nanda from The University of Chicago to discuss the patient experience associated with the diagnosis and treatment of metastatic triple-negative breast cancer.

Metastatic Breast Cancer — San Antonio 2024 symposium series proceedings Part 3 Jan 10, 2025

Dr Erika Hamilton from the Sarah Cannon Research Institute in Nashville, Tennessee, Dr Kevin Kalinsky from the Winship Cancer Institute of Emory University in Atlanta, Georgia, Dr Ian E Krop from the Yale Cancer Center in New Haven, Connecticut, Dr Joyce O’Shaughnessy from the Sarah Cannon Research Institute in Dallas, Texas, and Dr Sara M Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, discuss available and novel treatment strategies for metastatic breast cancer.

The Role of Endocrine-Based Therapy in the Management of Breast Cancer — San Antonio 2024 symposium series proceedings Part 2 Jan 03, 2025

Dr Matthew Goetz from Mayo Clinic Comprehensive Cancer Center in Rochester, Minnesota, Dr Sara Hurvitz from Fred Hutchinson Cancer Center in Seattle, Washington, Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, Virginia Kaklamani from UT Health San Antonio MD Anderson Cancer Center in Texas, and Dr Seth Wander from Massachusetts General Hospital in Boston share their perspectives on the management of hormone receptor-positive breast cancers and the potential role of emerging data from SABCS 2024.

HER2-Low and HER2-Ultralow Breast Cancer — San Antonio 2024 symposium series proceedings Part 1 Dec 23, 2024

Dr Aditya Bardia, Professor Giuseppe Curigliano, Dr Hope Rugo and Dr Antonio C Wolff share their perspectives on the management of HER2-low breast cancer and the potential role of emerging data from SABCS 2024.

5-Minute Journal Club Issue 2 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer Dec 16, 2024

Dr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer.

Exploring the Current Management Paradigm for Patients with Metastatic Triple-Negative Breast Cancer Dec 05, 2024

Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood and Dr Sara M Tolaney from Dana-Farber Cancer Center in Boston discuss recent updates on available and novel treatment strategies for metastatic triple-negative breast cancer.

5-Minute Journal Club Issue 1 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer Nov 26, 2024

Dr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral selective estrogen receptor degraders for ER-positive metastatic breast cancer.

Optimizing Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer Harboring PI3K/AKT/PTEN Pathway Abnormalities Nov 19, 2024

Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Hope S Rugo from the UCSF Helen Diller Family Comprehensive Cancer Center discuss treatment decision-making for HR-positive metastatic breast cancer in patients who harbor PI3K/AKT/PTEN pathway mutations.

Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care  — Breast Cancer Nov 15, 2024

Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with HR-positive breast cancer.

Improving Outcomes with First-Line Endocrine-Based Therapy for Patients with HR-Positive, HER2-Negative Metastatic Breast Cancer Nov 01, 2024

Prof Francois-Clement Bidard from Institut Curie in Paris and Dr Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta discuss improving the outcomes of first-line endocrine-based therapy for patients with HR-positive, HER2-negative metastatic breast cancer.

Oncology Today with Dr Neil Love: Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast Cancer Oct 25, 2024

Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville discusses emerging evidence with proteolysis-targeting chimera estrogen receptor degraders for HR-positive metastatic breast cancer.

Practical Perspectives: Optimizing Diagnosis and Treatment for Patients with Desmoid Tumors Oct 18, 2024

Dr Thierry Alcindor from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Mrinal Gounder from Memorial Sloan Kettering Cancer Center in New York, New York, summarize the treatment landscape for desmoid tumors and review novel options for targeted therapy.

Oncology Today with Dr Neil Love: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer Sep 25, 2024

Dr Tiffany Traina from the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College in New York, New York, discusses optimizing the management of metastatic BRCA-negative, triple-negative breast cancer.

Inside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer Sep 06, 2024

Prof Peter Schmid from the Barts Cancer Institute in London, United Kingdom, and Dr Sara Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, review clinical trials investigating the role of antibody-drug conjugate-mediated therapies in the treatment of metastatic breast cancer.

Oncology Today with Dr Neil Love: Special Edition — Key Presentations on Breast Cancer from the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Aug 29, 2024

Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, discusses recent advances in the treatment of breast cancer following the 2024 ASCO Annual Meeting.

Oncology Today with Dr Neil Love: An interview with Professor Giuseppe Curigliano, MD, PhD — Management of Metastatic Breast Cancer Aug 23, 2024

Prof Giuseppe Curigliano from the European Institute of Oncology in Milano, Italy discusses current questions and controversies in the management of metastatic breast cancer.

Oncology Today with Dr Neil Love: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer Aug 16, 2024

Dr Sara A Hurvitz from the Fred Hutchinson Cancer Center in Seattle, Washington, summarizes recent trials investigating the integration of antibody-drug conjugates for HR-positive and triple-negative metastatic breast cancer.

Individualizing the Selection of First-Line Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer Aug 07, 2024

Dr Joyce O’Shaughnessy from Sarah Cannon Research Institute in Dallas, Texas, summarizes risk factors and targeted therapy options for patients with HR-positive metastatic breast cancer.

Oncology Today with Dr Neil Love: Optimizing the Identification of HER2-Low Breast Cancer Jul 31, 2024

Dr Kimberly H Allison from Stanford Cancer Institute in Stanford, California, discusses the optimal identification, pathologic reporting and treatment of HER2-low breast cancer.

What Clinicians Want to Know About the Management of Triple-Negative Breast Cancer Jul 11, 2024

Dr Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr Heather McArthur from UT Southwestern Medical Center in Dallas, Texas, summarize the evolution of biomarker-driven treatment approaches for triple-negative breast cancer.

Striving for Consensus: Exploring the Current Role of Ovarian Suppression in the Management of Breast Cancer Jun 13, 2024

Dr William J Gradishar from Northwestern Medicine Feinberg School of Medicine in Chicago, Illinois, Dr Virginia Kaklamani from UT Health San Antonio MD Anderson Cancer Center in Texas, Dr Erica Mayer from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Seth Wander from Massachusetts General Hospital in Boston, discuss key findings and practical considerations with ovarian function suppression for hormone receptor-positive breast cancer.

Oncology Today with Dr Neil Love: Understanding the Risk of Recurrence and Related Management for Patients with Localized HER2-Positive Breast Cancer May 21, 2024

Dr Adam M Brufsky from UPMC Hillman Cancer Center in Pittsburgh summarizes the history of and modern advances in treating localized HER2-positive breast cancers, including strategies for monitoring and managing treatment-related toxicities.

Virtual Case Library: Metastatic Triple-Negative Breast Cancer May 09, 2024

Drs Rita Nanda, Sara M Tolaney, Julia Foldi, Laura Huppert and Saba Shaikh discuss available and emerging research, patient cases from participating junior clinical investigators and senior clinical investigator perspectives on relevant research data informing clinical decision-making for patients with metastatic triple-negative breast cancer.

Oncology Today with Dr Neil Love: Overcoming Endocrine Resistance in ER-Positive Metastatic Breast Cancer Mar 26, 2024

Dr Seth Wander from Harvard Medical School in Boston, Massachusetts, discusses mechanisms underlying endocrine resistance in breast cancer and optimal therapeutic approaches for patients who experience disease progression while or after receiving endocrine therapy.

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in HER2-Positive and Triple-Negative Breast Cancer Mar 15, 2024

Dr Ian E Krop from the Yale Cancer Center in New Haven, Connecticut, and Dr Priyanka Sharma from the University of Kansas Cancer Center in Westwood, Kansas, discuss patient cases and treatment strategies for HER2-positive and triple-negative breast cancer.

Oncology Today with Dr Neil Love: Understanding the Current and Future Role of Oral SERDs (Selective Estrogen Receptor Degraders) in the Management of ER-Positive Metastatic Breast Cancer Mar 11, 2024

Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York City discusses available and emerging data with oral SERDs for patients with ER-positive metastatic breast cancer.

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hormone Receptor-Positive Breast Cancer Feb 01, 2024

Dr Stephanie L Graff from the Legorreta Cancer Center at Brown University in Providence, Rhode Island, and Dr Erica Mayer from Dana-Farber Cancer Institute in Boston discuss treatment decision-making involving approved and investigational strategies for the management of hormone receptor-positive breast cancer.

Implications of Recent Data Sets for the Current and Future Management of Breast Cancer Nov 30, 2023

Dr Aditya Bardia from Massachusetts General Hospital and Dr Sara M Tolaney from the Dana-Farber Cancer Institute, both in Boston, Massachusetts, discuss key presentations on the management of breast cancer from the 2023 ESMO Congress.

Inside the Issue: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer Sep 29, 2023

Dr Hope Rugo from the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California, and Dr Tiffany Traina from Memorial Sloan Kettering Cancer Center in New York, New York, discuss current and emerging optimal management approaches for metastatic triple-negative breast cancer.

Meet The Professor: Optimizing the Management of Soft Tissue Sarcoma and Related Connective Tissue Disorders — Part 2 of a 2-Part Series Aug 30, 2023

Dr Richard F Riedel from Duke Cancer Institute in Durham, North Carolina, discusses approved and novel treatment approaches for soft tissue sarcoma, moderated by Dr Neil Love.

Inside the Issue: Current and Future Management of ER-Positive Metastatic Breast Cancer After Disease Progression on a CDK4/6 Inhibitor Aug 24, 2023

Dr Aditya Bardia from Massachusetts General Hospital in Boston, Massachusetts, and Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discuss approved and novel treatment approaches for ER-positive metastatic breast cancer that has progressed on prior CDK4/6 inhibitor therapy.

Oncology Today with Dr Neil Love: Special Edition — Key Presentations on Breast Cancer from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Aug 09, 2023

Dr Heather McArthur from the UT Southwestern Medical Center in Dallas, Texas discusses key presentations on breast cancer from the 2023 ASCO Annual meeting.

Oncology Today with Dr Neil Love: Special Edition — Current and Future Management of Breast Cancer Jul 21, 2023

Featuring a discussion on recent presentations in breast cancer from the 2023 ASCO annual meeting with Dr Kevin Kalinsky, moderated by Dr Neil Love.

Meet The Professor: Optimizing the Management of Soft Tissue Sarcoma and Related Connective Tissue Disorders — Part 1 of a 2-Part Series Jun 16, 2023

Featuring a discussion on the management of soft tissue sarcoma and related connective tissue disorders with Dr Brian Van Tine, moderated by Dr Neil Love.

Meet The Professor: Optimizing the Management of ER-Positive and Triple-Negative Breast Cancer — Part 3 of a 3-Part Series Apr 27, 2023

Featuring a discussion on the management of ER-positive and triple-negative breast cancer with Dr Sara A Hurvitz, moderated by Dr Neil Love.

Meet The Professor: Optimizing the Management of ER-Positive and Triple-Negative Breast Cancer — Part 2 of a 3-Part Series Mar 31, 2023

Featuring a discussion on the management of ER-positive and triple-negative breast cancer with Dr Sara Tolaney, moderated by Dr Neil Love. ?

Recent Advances and Future Directions in Breast Cancer — With Dr Harold Burstein and Dr Virginia Kaklamani (Proceedings from a Symposium in Partnership with NCOA and SCOS) Mar 17, 2023

Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in breast cancer, gastrointestinal cancers, genitourinary cancers, chronic lymphocytic leukemia and lymphomas, gynecologic cancers and lung cancer. Featuring perspectives from Drs Tanios Bekaii-Saab, Michael Birrer, Danielle Brander, Harold Burstein, Ibiayi Dagogo-Jack, Virginia Kaklamani, Stephen Liu, Ursula Matulonis, Rutika Mehta, Craig Moskowitz, Daniel Petrylak and Sandy Srinivas.

Inside the Issue — Exploring the Current Role of Ovarian Suppression in the Management of Breast Cancer Mar 10, 2023

Featuring a discussion on the current role of ovarian suppression in the management of breast cancer with Drs Kathy Miller and Ann Partridge, moderated by Dr Neil Love.

Meet The Professor: Optimizing the Management of ER-Positive and Triple-Negative Breast Cancer — Part 1 of a 3-Part Series Feb 24, 2023

Featuring a discussion on the management of ER-positive and triple-negative breast cancer with Dr Komal Jhaveri, moderated by Dr Neil Love.

Oncology Today with Dr Neil Love: Special Edition — Management of ER-Positive Breast Cancer Jan 31, 2023

Featuring a discussion on ER-positive breast cancer with Drs Erica Mayer and Ruth O’Regan, moderated by Dr Neil Love.

Oncology Today with Dr Neil Love: HER2-Positive Metastatic Breast Cancer Jan 26, 2023

Featuring a discussion of recent advances in the treatment of HER2-positive metastatic breast cancer with Professor Giuseppe Curigliano, moderated by Dr Neil Love.

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Breast Cancer Jan 17, 2023

Proceedings from our Year in Review webinar on the management of breast cancer. Featuring perspectives from Dr Joyce O’Shaughnessy and Prof Peter Schmid, moderated by Dr Neil Love.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected